Arcalyst
Payments companies reported to CMS as associated with Arcalyst. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Arcalyst, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Arcalyst
These are the largest totals companies reported as associated with Arcalyst. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $115,383.28 |
| Robert Biederman | Charleston, SC | Cardiovascular Disease | $108,295.07 |
| David Homan | Opelousas, LA | Interventional Cardiology | $69,949.09 |
| John Isaac | Houston, TX | Interventional Cardiology | $62,448.22 |
| Krishnaswami Vijayaraghavan | Scottsdale, AZ | Cardiovascular Disease | $53,347.72 |
| Ajit Raisinghani | San Diego, CA | Cardiovascular Disease | $46,293.69 |
| Dor Lotan | New York, NY | Advanced Heart Failure and Transplant Cardiology | $39,257.50 |
| Amin Sabet | Fresno, CA | Cardiovascular Disease | $36,095.92 |
| Dipan Shah | Houston, TX | Cardiovascular Disease | $34,116.86 |
| Rigved Tadwalkar | Santa Monica, CA | Cardiovascular Disease | $33,814.13 |
Prescribed Arcalyst?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.